Open Access

CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients

  • Authors:
    • Huda Al Sayed Ahmed
    • Wasim Fawzi Raslan
    • Abdel Halim Salem Deifalla
    • Mohammad Dahmani Fathallah
  • View Affiliations

  • Published online on: April 24, 2019     https://doi.org/10.3892/mco.2019.1850
  • Pages: 67-76
  • Copyright: © Al Sayed Ahmed et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hodgkin's lymphoma (HL) is a hematological malignancy characterized by a minority of neoplastic cells outnumbered by tumor‑associated macrophages (TAMs). The overexpression of the CD163 antigen by TAMs is considered to be a significant predictive biomarker for risk stratification. This is likely caused by a genetic single‑nucleotide polymorphism (SNP) at the gene promoter. The aim of the present retrospective case‑control study was to establish a gene expression profile of a specific biomarker for classical HL (CHL) in order to predict the outcome and survival of CHL patients in Saudi Arabia. The protein expression of CD163 on TAMs was studied using immunohistochemistry (IHC). A prognosis index was calculated for the CD163 protein to assess the risk stratification of CHL. Genotyping of selected SNPs of this antigen was performed for 100 CHL cases and controls. The analysis revealed that the CD163 protein expression level was significantly correlated with disease relapse (DR) and overall survival (OS). In addition, the CD163 index threshold (15.0) was found to be significantly correlated with the relapse rate. Among the studied CD163 SNPs, rs75608120 exhibited a significant correlation with the DR rate of CHL patients, but not with OS. The findings of the present study confirmed that CD163 is a specific marker for TAMs, and its overexpression by TAMs is significantly associated with relapse and reduced survival post‑therapy. In addition, a new methodology of indexing CD163 protein expression for HL risk stratification was proposed. Thus, the present study identified a specific predictive molecular and antigenic biomarker for CHL prognosis.

References

1 

Rauf MS, Akhtar S and Maghfoor I: Changing trends of adult lymphoma in the kingdom of Saudi Arabia-comparison of data sources. Asian Pac J Cancer Prev. 16:2069–2072. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Leukemia and Lymphoma Society, . American Cancer Society Cancer Facts and Figures 2016; GLOBOCAN 2012; ClinicalTrials.gov. CRI grantee progress reports and other CRI grantee documents. 2016, simplehttp://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/lymphoma#sthash.9EkuimDH.dpuf 91November 14–2014

3 

Al-Madouj AN, Eldali A and Al-Zahrani AS: Ten year cancer incidence among nationals of the GCC states. Gulf center for cancer control and prevention, king faisal specialist hospital and research center. 2011, simplehttp://www.moh.gov.bh/Content/Files/Publications/GCC%20Cancer%20Incidence%202011.pdfSeptember 1–2011

4 

Cancer Incidence Report Saudi Arabia 2013, . simplehttp://www.chs.gov.sa/Ar/HealthCenters/NCC/CancerRegistry/CancerRegistryReports/2013June 1–2016

5 

Maggioncalda A, Malik N, Shenoy P, Smith M, Sinha R and Flowers CR: Clinical, molecular, and environmental risk factors for Hodgkin lymphoma. Adv Hematol. 2011:7362612011. View Article : Google Scholar : PubMed/NCBI

6 

Al-Diab AI, Siddiqui N, Sogiawalla FF and Fawzy EM: The changing trends of adult Hodgkin's disease in Saudi Arabia. Saudi Med J. 24:617–622. 2003.PubMed/NCBI

7 

Piccaluga PP, Agostinelli C, Gazzola A, Tripodo C, Bacci F, Sabattini E, Sista MT, Mannu C, Sapienza MR, Rossi M, et al: Pathobiology of hodgkin lymphoma. Adv Hematol. 2011:9208982011. View Article : Google Scholar : PubMed/NCBI

8 

Montes-Moreno S: Hodgkin's lymphomas: A tumor recognized by its microenvironment. Adv Hematol. 2011:1423952011. View Article : Google Scholar : PubMed/NCBI

9 

Smith LB: Nodular lymphocyte predominant Hodgkin lymphoma: Diagnostic pearls and pitfalls. Arch Pathol Lab Med. 134:1434–1439. 2010.PubMed/NCBI

10 

Carbone PP, Kaplan HS, Musshoff K, Smithers DW and Tubiana M: Report of the committee on Hodgkin's disease staging classification. Cancer Res. 31:1860–1861. 1971.PubMed/NCBI

11 

Hasenclever D and Diehl V: A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med. 339:1506–1514. 1998. View Article : Google Scholar : PubMed/NCBI

12 

Canioni D, Deau-Fischer B, Taupin P, Ribrag V, Delarue R, Bosq J, Rubio MT, Roux D, Vasiliu V, Varet B, et al: Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: A study of 59 cases. PLoS One. 4:e63412009. View Article : Google Scholar : PubMed/NCBI

13 

Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Shenkier TN, Slack GW, Skinnider B, Gascoyne RD, et al: International prognostic score in advanced-stage Hodgkin's lymphoma: Altered utility in the modern era. J Clin Oncol. 30:3383–3388. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Henry-Amar M, Friedman S, Hayat M, Somers R, Meerwaldt JH, Carde P, Burgers JM, Thomas J, Monconduit M and Noordijk EM: Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC lymphoma cooperative group. Ann Intern Med. 114:361–365. 1991. View Article : Google Scholar : PubMed/NCBI

15 

Roshal M, Wood BL and Fromm JR: Flow cytometric detection of the classical hodgkin lymphoma: Clinical and research applications. Adv Hematol. 2011:3870342011. View Article : Google Scholar : PubMed/NCBI

16 

Dunphy CH: Applications of flow cytometry and immunohistochemistry to diagnostic hematopathology. Arch Pathol Lab Med. 128:1004–1022. 2004.PubMed/NCBI

17 

Scott DW and Steidl C: The classical Hodgkin lymphoma tumor microenvironment: Macrophages and gene expression-based modeling. Hematology Am Soc Hematol Educ Program. 2014:144–150. 2014. View Article : Google Scholar : PubMed/NCBI

18 

Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, et al: Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: A correlative study from the E2496 Intergroup trial. Blood. 120:3280–3287. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Mallmann MR, Schmidt SV and Schultze JL: Macrophages in human cancer: Current and future aspects. Atlas Genet Cytogenet Oncol Haematol. 16:765–774. 2012.

20 

Ruhrberg C and De Palma M: A double agent in cancer: Deciphering macrophage roles in human tumors. Nat Med. 16:861–862. 2010. View Article : Google Scholar : PubMed/NCBI

21 

Ree HJ and Kadin ME: Macrophage-histiocytes in Hodgkin's disease. The relation of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease. Cancer. 56:333–338. 1985. View Article : Google Scholar : PubMed/NCBI

22 

Guo B, Cen H, Tan X and Ke Q: Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma. BMC Med. 14:1592016. View Article : Google Scholar : PubMed/NCBI

23 

Sud A, Thomsen H, Sundquist K, Houlston RS and Hemminki K: Risk of second cancer in Hodgkin lymphoma survivors and influence of family history. J Clin Oncol. 35:1584–1590. 2017. View Article : Google Scholar : PubMed/NCBI

24 

Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, et al: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 362:875–885. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Sánchez-Espiridión B, Montalbán C, López A, Menárguez J, Sabín P, Ruiz-Marcellán C, Lopez A, Ramos R, Rodríguez J, Cánovas A, et al: A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood. 116:e12–17. 2010. View Article : Google Scholar : PubMed/NCBI

26 

Gregory AD and Houghton AM: Tumor-associated neutrophils: New targets for cancer therapy. Cancer Res. 71:2411–2416. 2011. View Article : Google Scholar : PubMed/NCBI

27 

Wahl LM and Kleinman HK: Tumor-associated macrophages as target for cancer therapy. J Natl Cncer Inst. 90:1583–1584. 1998. View Article : Google Scholar

28 

Derenzini E and Younes A: Predicting treatment outcome in classical Hodgkin lymphoma: Genomic advances. Genome Med. 3:262011. View Article : Google Scholar : PubMed/NCBI

29 

Barros MH, Segges P, Vera-Lozada G, Hassan R and Niedobitek G: Macrophage polarization reflects T cell composition of tumor microenvironment in pediatric classical Hodgkin lymphoma and has impact on survival. PLoS One. 10:e01245312015. View Article : Google Scholar : PubMed/NCBI

30 

Yoon DH, Koh YW, Kang HJ, Kim S, Park CS, Lee SW, Suh C and Huh J: CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol. 88:292–305. 2012. View Article : Google Scholar : PubMed/NCBI

31 

Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC and Spector N: Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol. 23:736–742. 2012. View Article : Google Scholar : PubMed/NCBI

32 

Lau SK, Chu PG and Weiss LM: CD163: A specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol. 122:794–801. 2004. View Article : Google Scholar : PubMed/NCBI

33 

Ritter M, Buechler C, Langmann T, Orso E, Klucken J and Schmitz G: The scavenger receptor CD163: Regulation, promoter structure and genomic organization. Pathobiology. 67:257–261. 1999. View Article : Google Scholar : PubMed/NCBI

34 

Harris JA, Jain S, Ren Q, Zarineh A, Liu C and Ibrahim S: CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol. 7:122012. View Article : Google Scholar : PubMed/NCBI

35 

El-Zein R, Monroy CM, Etzel CJ, Cortes AC, Xing Y, Collier AL and Strom SS: Genetic polymorphisms in DNA repair genes as modulators of Hodgkin disease risk. Cancer. 115:1651–1659. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

July 2019
Volume 11 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Al Sayed Ahmed, H., Raslan, W.F., Deifalla, A.H., & Fathallah, M.D. (2019). CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients. Molecular and Clinical Oncology, 11, 67-76. https://doi.org/10.3892/mco.2019.1850
MLA
Al Sayed Ahmed, H., Raslan, W. F., Deifalla, A. H., Fathallah, M. D."CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients". Molecular and Clinical Oncology 11.1 (2019): 67-76.
Chicago
Al Sayed Ahmed, H., Raslan, W. F., Deifalla, A. H., Fathallah, M. D."CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients". Molecular and Clinical Oncology 11, no. 1 (2019): 67-76. https://doi.org/10.3892/mco.2019.1850